Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 7:12:359-369.
doi: 10.1016/j.omtn.2018.05.018. Epub 2018 Jul 3.

The Impact of lncRNA Dysregulation on Clinicopathology and Survival of Breast Cancer: A Systematic Review and Meta-analysis

Tian Tian  1 , Meng Wang  1 , Shuai Lin  1 , Yan Guo  2 , Zhiming Dai  3 , Kang Liu  1 , Pengtao Yang  1 , Cong Dai  1 , Yuyao Zhu  1 , Yi Zheng  1 , Peng Xu  1 , Wenge Zhu  4 , Zhijun Dai  5
Affiliations

The Impact of lncRNA Dysregulation on Clinicopathology and Survival of Breast Cancer: A Systematic Review and Meta-analysis

Tian Tian et al. Mol Ther Nucleic Acids. .

Abstract

Dysregulation of multiple long non-coding RNAs (lncRNAs) was reported to play major roles in breast cancer (BC). Here we aimed to collect most of the relevant literature to assess the prognostic value of lncRNAs in BC. To this end, we systematically searched PubMed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wanfang to identify published articles on the associations of lncRNAs with clinicopathology and/or survival of BC. Via this searching, we identified 70 articles involving 9,307 BC patients and regarding 48 lncRNAs. The expression of 41 lncRNAs was related to one or more clinicopathological parameters of BC, including tumor size; lymph node metastasis; histological grade; TNM stage; and estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) statuses (p < 0.05). Dysregulation of 28 lncRNAs was associated with overall survival, and abnormal expression of 9 lncRNAs was linked to disease-free survival. Furthermore, the expression level of 3 lncRNAs was correlated with metastasis-free survival, 3 lncRNAs with relapse-free survival, and 3 lncRNAs with progression-free survival. Our analysis showed that multiple lncRNAs were significantly associated with BC clinicopathology and survival. A large-scale study is needed to verify the prognostic value of these lncRNAs in BC.

Keywords: breast cancer; clinicopathology; long non-coding RNA; prognosis; survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Forest Plots of the Significant Associations between the Expression of Five lncRNAs and Clinical Features of Breast Cancer Each square indicates a study, and the area of squares is proportional to the weight of the study. The diamond represents the pooled OR and 95% CI.
Figure 2
Figure 2
Forest Plots of the Associations between the Expression of Five lncRNAs and Breast Cancer Overall Survival Each square indicates a study and the area of squares is proportional to the weight of the study. The diamond represents the pooled HR and 95% CI.
Figure 3
Figure 3
Forest Plots of the Associations between the Expression of Two lncRNAs and Breast Cancer Metastasis-free Survival Each square indicates a study and the area of squares is proportional to the weight of the study. The diamond represents the pooled HR and 95% CI.
Figure 4
Figure 4
Forest Plots of the Associations between the Expression of lncRNAs and Breast Cancer Overall Survival in Single Studies Each square indicates a study.
Figure 5
Figure 5
Flow Diagram of the Literature Review Process A total of 991 articles were found by searching databases. After removing duplication, 732 articles were screened by title and abstract. Then, 111 articles were reviewed for full-text and 70 articles were finally included.
See this image and copyright information in PMC

References

    1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015;65:87–108. - PubMed
    1. Smith R.A., Andrews K., Brooks D., DeSantis C.E., Fedewa S.A., Lortet-Tieulent J., Manassaram-Baptiste D., Brawley O.W., Wender R.C. Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J. Clin. 2016;66:96–114. - PubMed
    1. Shi J.F., Huang H.Y., Guo L.W., Shi D., Gu X.Y., Liang H., Wang L., Ren J.S., Bai Y.N., Mao A.Y. Quality-of-life and health utility scores for common cancers in China: a multicentre cross-sectional survey. Lancet. 2016;388(Suppl 1):S29.
    1. Hayes D.F. Prognostic and predictive factors revisited. Breast. 2005;14:493–499. - PubMed
    1. Tang X. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 2013;332:3–10. - PubMed